The new report by Expert Market Research titled, ‘Global PD-1 and PD-L1 Inhibitors Market Report and Forecast 2022-2027’, gives an in-depth analysis of the global PD-1 and PD-L1 inhibitors market, assessing the market based on its segments like type, applications, end-user, and major regions. The report tracks the latest trends in the industry and studies their impact on the overall market. It also assesses the market dynamics, covering the key demand and price indicators and analyzing the market based on the SWOT and Porter’s Five Forces models.
Get a Free Sample Report with Table of Contents@ https://www.expertmarketresearch.com/reports/pd-1-and-pd-l1-inhibitors-market/requestsample
PD-1 and PD-L1 Inhibitors Market Share, Size, Trends, Industry Report, Key Player, Major Segments, and Forecast
The key highlights of the report include:
Market Overview (2017-2027)
• Historical Market Size (2021): USD 30.3 billion
• Forecast CAGR (2022-2027): 17.50%
• Forecast Market Size (2027): USD 80.9 billion
| Report Attribute | Details |
| Historical Period | 2017-2021 |
| Forecast Period | 2022-2027 |
| Base Year | 2021 |
| Market Size in 2021 | 30.3 billion |
| Revenue Forecast in 2027 | 80.9 billion |
| Growth Rate CAGR | 17.50% |
| Major Players | Sanofi S.A., F. Hoffmann-La Roche AG, Amgen Inc., Pfizer Inc. AstraZeneca PLC, and Bristol-Myers Squibb Company. |
The global market for PD-1 and PD-L1 inhibitors is being driven by the increasing incidences of cancer among people. In several countries, cancer is one of the major causes of death of people, and this is creating a demand for better treatment methods for cancer. Furthermore, the growing geriatric population is also contributing to the market growth of PD-1 and PD-L1 inhibitors.
PD-1 and PD-L1 Inhibitors Industry Definition and Major Segments
PD-1 and PD-L1 inhibitors are the leading methods of treatment for multiple types of cancer. These are a group of immune checkpoint inhibitors. Some examples of drugs with target PD-1 include Pembrolizumab (Keytruda), Nivolumab (Opdivo), and Cemiplimab (Libtayo).
Read Full Report with Table of Contents@ https://www.expertmarketresearch.com/reports/pd-1-and-pd-l1-inhibitors-market
Based on type, the market is segmented into:
• PD-1 Inhibitors
• PD-L1 Inhibitors
Depending on the application, the market is bifurcated into:
• Hodgkin Lymphoma
• Kidney Cancer
• Melanoma
• Non-Small Cell Lung Cancer
• Others
Based on the user of PD-1 and PD-L1 Inhibitors, the market has been divided as:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
For an in-depth analysis, the market has also been divided into regional markets, namely North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
PD-1 and PD-L1 Inhibitors Market Trends
The use of PD1/PD-L1-targeted monoclonal antibodies has emerged as a major treatment method for numerous types of cancer. In countries like India, the cases of cancer are constantly growing. As per the 2020 report of the Indian Council of Medical Research (ICMR) and the National Centre for Disease Informatics and Research (NCDIR), the cases of cancer in India are likely to grow by 12% in the coming five years. Such a rise in the cases of cancer is propelling governments and other non-profit organizations to raise funds for the treatment of cancer.
Key Market Players
The major players in the PD-1 and PD-L1 inhibitors market are:
- Sanofi S.A.
- Hoffmann-La Roche AG
- Amgen Inc.
- Pfizer Inc.
- AstraZeneca PLC
- Bristol-Myers Squibb Company
- Others
The report covers the market capacities, shares, expansions, plant turnarounds, investments and mergers and acquisitions, among other latest developments of these market players.
About Us:
Expert Market Research (EMR) is leading market research company with clients across the globe. Through comprehensive data collection and skillful analysis and interpretation of data, the company offers its clients extensive, latest and actionable market intelligence which enables them to make informed and intelligent decisions and strengthen their position in the market. The clientele ranges from Fortune 1000 companies to small and medium scale enterprises.
EMR customizes syndicated reports according to clients’ requirements and expectations. The company is active across over 15 prominent industry domains, including food and beverages, chemicals and materials, technology and media, consumer goods, packaging, agriculture, and pharmaceuticals, among others.
Over 3000 EMR consultants and more than 100 analysts work very hard to ensure that clients get only the most updated, relevant, accurate and actionable industry intelligence so that they may formulate informed, effective and intelligent business strategies and ensure their leadership in the market.
Media Contact
Company Name: Claight Corporation
Contact Person:- Jessica Lucas, Business Consultant
Email: sales@expertmarketresearch.com
Toll Free Number: US +1-415-325-5166 | UK +44-702-402-5790
Address: 30 North Gould Street, Sheridan, WY 82801, US
Website: https://www.expertmarketresearch.com
LinkedIn:- https://www.linkedin.com/company/expert-market-research
0 Comments:
Post a Comment